



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/415	A2	(11) International Publication Number: WO 97/02821 (43) International Publication Date: 30 January 1997 (30.01.97)
(21) International Application Number: PCT/JP96/01872 (22) International Filing Date: 5 July 1996 (05.07.96) (30) Priority Data: 07/196174 8 July 1995 (08.07.95) JP (71) Applicant (for all designated States except US): NIHON NOHYAKU CO., LTD. [JP/JP]; 2-5, Nihonbashi 1-chome, Chuo-ku, Tokyo 103 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): KODAMA, Hiroki [JP/JP]; 685-7, Tokikita, Sakai-shi, Osaka 588 (JP). NIWANO, Yoshimi [JP/JP]; 7-330-1-408, Imakuma, Osakayama-shi, Osaka 589 (JP). KANAI, Kazuo [JP/JP]; 1-8, Shorinji-cho, Higashi-cho, Sakai-shi, Osaka 590 (JP). YOSHIDA, Masanori [JP/JP]; 5-3, Koyodai 2-chome, Hashimoto-shi, Wakayama 648 (JP). (74) Agents: HAGINO, Taira et al.; Eikoh Patent Office, Ark Mori Building, 28th floor, 12-32, Akasaka 1-chome, Minato-ku, Tokyo 107 (JP).		(81) Designated States: AT, AU, CA, CH, CN, DE, DK, ES, FI, GB, IL, KR, LU, MX, NO, NZ, PT, SE, US, European patent (BE, FR, GR, IT, NL). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: ANTIFUNGAL AGENT, COMPOUND THEREFOR, PROCESS FOR PRODUCING THE SAME (57) Abstract <p>R-(+)-(E)-[4-(2-Chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile, R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile, and pharmaceutically acceptable salts thereof which can be used as a pharmaceutical agent are disclosed. A process for producing them and a method for treating mycoses using them are also disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DESCRIPTION

ANTIFUNGAL AGENT, COMPOUND THEREFOR, PROCESS FOR PRODUCING THE SAME

Technical Field

The present invention relates to an antifungal agent,
a method for preventing or treating mycoses using the
antifungal agent, a novel optically active derivative and a
5 salt thereof, and a process for producing the derivative.

Background Art

Various azole compounds having antifungal activity have
been known. For example, JP-A-60-218387 discloses imidazole
compounds represented by the following formula (a) (the term
10 "JP-A" as used herein means an "unexamined published Japanese
patent application"):




Moreover, JP-A-62-93227 discloses that these compounds
are useful as an antifungal agent. Furthermore, JP-A-2-275877
15 discloses that the optically active compounds of specific
compounds among the above imidazole compounds have antifungal
activity against *Trichophyton mentagrophytes* about 1.4 times
the activity of racemic compounds thereof.

Disclosure of the Invention

An object of the present invention is to provide antifungal agents comprising optically active compounds having more excellent antifungal activity than racemic compounds thereof.

Another object of the present invention is to provide the optically active compounds, a process for producing them, and a method for using them.

These and other objects of the present invention have been attained by a pharmaceutical composition comprising as an active ingredient R-(+)-(E)-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile (hereinafter referred to as "Compound (A)") or R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile (hereinafter referred to as "Compound (B)") represented by the following formula (I):



wherein R represents a hydrogen atom or a chlorine atom, or a pharmaceutically acceptable salt thereof; together with a pharmaceutically acceptable carrier or diluent.

Furthermore, these and other objects of the present invention have been attained by Compound (B) or a salt thereof.

Moreover, these and other objects of the present invention have been attained by a process for producing Compound (B) which comprises reacting an optically active glycol derivative represented by the following formula (II) or an equivalent thereof with a compound represented by the following formula (III):



wherein X₁ and X₂ are the same or different and each represents a methanesulfonyloxy group, a benzenesulfonyloxy group, a p-toluenesulfonyloxy group, or a halogen atom:



wherein M represents an alkali metal atom.

Still furthermore, these and other objects of the present invention have been attained by a method for preventing or treating mycosis which comprises administering to human or animals in need of such prevention or treatment a pharmaceutically effective amount of Compound (A) or Compound


(B), or a pharmaceutical acceptable salt thereof; optionally together with a pharmaceutical acceptable carrier or diluent.

Still moreover, these and other objects of the present invention have been attained by use of Compound (A) or Compound (B), or a pharmaceutically acceptable salt thereof for
5 preparing a pharmaceutical composition.


Best Mode for Practicing Invention

Specifically, Compounds (A) and (B) are shown below.

Compound (A):



10 Compound (B):




The present inventors have found that Compound (A) or Compound (B) represented by formula (I) and pharmaceutically acceptable salts thereof, namely, (R)-enantiomers, have antifungal activity several times that of racemic mixtures thereof against dermatophytes, especially highly sensitive
15 strains, and that Compound (B) which has not been described in

any literatures and is a novel compound has superior antifungal activity unexpected from the racemic mixtures thereof. Thus, the present invention has been accomplished.

Compounds (A) and (B) are highly sensitive to, especially, *Trichophyton rubrum*. The antifungal activity thereof is 2 to 4 times as high as that of the racemic mixtures thereof.

Compound (A) can be produced, for example, by the process disclosed in JP-A-2-275877. Compound (B) can be produced by the process illustrated below.




In formula, X₁ and X₂ are the same or different and each represents a methanesulfonyloxy group, a benzenesulfonyloxy group, a p-toluenesulfonyloxy group or a halogen atom; and M represents an alkali metal atom. Examples of the halogen atom

represented by X_1 or X_2 include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom. Examples of the alkali metal atom represented by M include Li, Na and K.

That is, in the same manner as described in JP-A-2-275877, Compound (B) can be produced by reacting an optically active glycol derivative having a configuration of (S) represented by formula (II) or an equivalent thereof with a dithiolate salt represented by formula (III).

The dithiolate salt represented by formula (III) can be produced by reacting 1-cyanomethylimidazole shown below with carbon disulfide in the presence of a base and an inert solvent.



In formula, M is the same as defined above.

Any inert solvents can be used in the above reaction as far as they do not inhibit the progress of the reaction. Examples thereof include alcohols (e.g., methanol, ethanol, isopropanol), polar solvents (e.g., dimethyl sulfoxide (DMSO), dimethylformamide, acetonitrile), water, and mixed solvents thereof.


Examples of the base include sodium carbonate, potassium carbonate, sodium hydroxide and potassium hydroxide. They can be used as they are in the form of solid or as a solution in an inert solvent. Amount (mol) of the base can be
5 selected from the range of 2 to 8 times, preferably 4 to 6 times, the amount (mol) of 1-cyanomethylimidazole.

The compound represented by formula (II) can be used in an amount equimolar to or in excess of 1-cyanomethylimidazole.

The reaction temperature can be selected from the range
10 of 0 to 100°C, and is preferably about room temperature. The reaction time can be selected from the range of 0.5 to 24 hours.

The resulting compound is a mixture of geometrical isomers E and Z, and the desired E-isomer represented by
15 formula (I) can be isolated and purified by, e.g., silica gel column chromatography, fractional crystallization. Examples of solvents for purification by fractional crystallization and recrystallization include ethanol, ethyl acetate, ether, hexane, acetone, and mixed solvents thereof, but these are not
20 limitative.


The optically active starting compounds represented by formula (II) can be produced by known processes 1 to 3 illustrated below.

Process 1:

5 In formula, X_1 and X_2 are the same as defined above.

That is, they can be produced by reacting (S)-1-(2,4-dichlorophenyl)ethane-1,2-diol obtainable from 2,4-dichlorostyrene by a known process [*J. Org. Chem. Soc.*, 57:2768 (1992)] with a suitable halogenating agent (e.g., thionyl chloride, phosphorus tribromide, carbon tetrachloride/triphenylphosphine) or an activating agent (e.g., methanesulfonyl chloride, toluenesulfonyl chloride, benzenesulfonyl chloride).

10


Process 2:

In formula, X represents a chlorine atom or a bromine atom; and X₂ is the same as defined above.

As illustrated above, the compounds represented by formula (II) in which X₁ is a chlorine atom or a bromine atom (i.e. the compounds represented by formula (IIa)) can be produced by reacting (R)-1-(2,4-dichlorophenyl)styrene oxide obtainable from 2,4-dichlorostyrene by a known process [*J. Am. Chem. Soc.*, 113:7063 (1991)] with a hydrogen halide to prepare a haloalcohol represented by formula (IV), and then reacting the haloalcohol with a suitable halogenating agent (e.g., thionyl chloride, phosphorus tribromide, carbon tetrachloride/triphenylphosphine) or an activating agent (e.g., methanesulfonyl chloride, toluenesulfonyl chloride, benzenesulfonyl chloride).

Process 3:

The compounds represented by formula (II) in which X_2 is a chlorine or bromine atom (i.e., the compounds represented by formula (IIb)) can be produced by process 3 shown below.



In formula, X represents a chlorine atom or a bromine atom; and X_1 is the same as defined above.

That is, the desired compounds can be obtained by reacting a haloalcohol represented by formula (V) which can be synthesized from a 2,4-dichlorophenacyl halide by a known process [*Modern Synthetic Methods*, 5:115 (1989)] with a suitable halogenating agent (e.g., thionyl chloride, phosphorus tribromide, carbon tetrachloride/triphenylphosphine) or an activating agent (e.g., methanesulfonyl chloride, toluenesulfonyl chloride, benzenesulfonyl chloride).

The compositions of the present invention are antifungal agents useful for curing mycotic infection of human or animals. For example, these can be used for curing local mycotic infection, mucosa mycotic infection, generalized mycotic infection caused by, e.g., fungi of the genera *Trichophyton*, *Candida*, and *Aspergillus*.

Compound (A), Compound (B) and a pharmaceutically acceptable salt thereof are each used alone or in the form of a composition comprising the compound and a pharmaceutically acceptable carrier or diluent. They are formed into
5 preparations suitable for oral or non-oral administration, such as liquid formulation, tablet, emulsion, ointment, cream, lotion, and poultice.

The amount administered can be any convenient amount according to age, body weight, and administration form, but is
10 normally at least 0.05 mg, preferably from 0.5 to 50 mg, per 1 kg of body weight and per one day for general treatment of adults and the agent can be administered at one time or several times in parts in one day.

In the case of local treatment, for example, in the
15 form of topical application, the concentration of the active ingredient is preferably at least 0.001%, more preferably from 0.1 to 2%. The amount of treatment is preferably from 30 to 100 mg per cm².

The antifungal agent of the present invention may be
20 used in admixture with other antifungal agents or antibacterial agents such as amphotericin B, trichomycin, varitotin, and clotrimazole.

Example

The present invention will now be illustrated in
25 greater detail with reference to the following Examples, Reference Examples, Formulation Examples, and Test Examples,

but it should be understood that the invention is not construed as being limited thereto. Unless otherwise indicated, all the percents are by weight.

EXAMPLE 1

5 Preparation of Compound (B) by Process 3:

1-(a). Preparation of (S)-1-(2,4-dichlorophenyl)-2-bromoethanol:




To 5 ml of dry tetrahydrofuran (THF) was added 300 mg of (S)-3,3-diphenyl-1-methyltetrahydro-1H,3H-pyrrolo-[1,2-c][1,3,2]oxazaborole, and then thereto was added dropwise
10 8 ml of 1.0 M borane-THF solution at -20°C. At the same temperature, thereto was further added dropwise a solution of 2.7 g of 2,4-dichlorophenacyl bromide in 8 ml of THF. The resultant mixture was heated to room temperature, and then
15 stirred for 3 hours. Next, 10 ml of methanol was added to decompose excess borane, and then the reaction mixture was poured into water and extracted with ether. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure
20 and the residue was purified by silica gel column chromatography (ethyl acetate/n-hexane = 1/3) to obtain 2.5 g of the desired product at an optical purity of 80%ee.

- 1-(b). Preparation of (S)-[1-(2,4-dichlorophenyl)-2-bromoethyl]methanesulfonate:



In 30 ml of methylene chloride was dissolved 1.6 g of (S)-1-(2,4-dichlorophenyl)-2-bromoethanol, and then 660 mg of triethylamine was added to the solution. Next, 750 mg of methanesulfonyl chloride was further added dropwise thereto under ice cooling. One hour after stirring at room temperature, the reaction mixture was washed with water and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 1.9 g of a crude product of the desired compound. The resulting crude product was used for the next reaction without purification.

- 1-(c). Preparation of (R)-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile (Compound (B)):



To 10 ml of DMSO was added 440 mg of potassium hydroxide, and, under cooling in a water bath, thereto was added dropwise a solution prepared by dissolving 300 mg of 1-

cyanomethylimidazole and 210 mg of carbon disulfide in 5 ml of
 DMSO, followed by stirring for 1 hour at room temperature to
 prepare a dithiolate solution. Then, the resulting dithiolate
 solution was added dropwise to a solution prepared by
 5 dissolving 950 mg of the crude product of (S)-1-[2,4-
 dichlorophenyl]-2-bromoethyl]methanesulfonate in 10 ml of DMSO
 under cooling in a water bath. Two hours after stirring at
 room temperature, the reaction mixture was poured into ice
 water and extracted with ethyl acetate. The organic layer was
 10 washed with water, and then dried over anhydrous magnesium
 sulfate. Next, the solvent was distilled off under reduced
 pressure. The residue was purified by silica gel column
 chromatography (ethyl acetate (AcOEt)/n-hexane = 2/1). The
 resulting crystal was recrystallized from a mixed solvent of
 15 ethyl acetate-n-hexane to obtain 350 mg of the desired product
 at an optical purity of 95%ee.

EXAMPLE 2

Preparation of Compound (B) by Process 1:


20 2-(a). Preparation of (S)-1-(2,4-dichlorophenyl)-ethane-1,2-
 bismethanesulfonate:



(S)-1-(2,4-Dichlorophenyl)-1,2-ethanediol (1.5 g;
 optical purity 98%ee) synthesized by a known process [J. Org.

Chem., 57:2768 (1992)] and 3.1 g of triethylamine were dissolved in 50 ml of methylene chloride and 3.3 g of methanesulfonyl chloride was added dropwise to the solution under ice cooling. Two hours after stirring at room temperature, the reaction mixture was washed with water and the organic layer was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 2.6 g of a crude product of the desired compound. The resulting crude product was used for the next reaction without purification.

2-(b). Preparation of (R)-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile (Compound (B)):



To 20 ml of DMSO was added 1.09 g of potassium hydroxide, and, under cooling in a water bath, thereto was added dropwise a solution prepared by dissolving 750 mg of 1-cyanomethylimidazole and 520 mg of carbon disulfide in 10 ml of DMSO, followed by stirring for 1 hour at room temperature to prepare a dithiolate solution. Then, under cooling in a water bath, the resulting dithiolate solution was added dropwise to a solution prepared by dissolving 2.61 g of the crude product of (S)-1-(2,4-dichlorophenyl)-ethane-1,2-bismethanesulfonate in

20 ml of DMSO. Two hours after stirring at room temperature, the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (AcOEt/n-hexane = 2/1). The resulting crystal was recrystallized from a mixed solvent of ethyl acetate-n-hexane to obtain 1.2 g of the desired product at an optical purity of 99%ee. In the above examples, the optical purity was calculated from area percentage in HPLC using an optical active HPLC column (Chiralcel OD (trademark, Daicel Chemical Industry Ltd.)).

REFERENCE EXAMPLE 1

Preparation of (±)-(E)-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile:

Synthesis was carried out by the process described in Example 1 of JP-A-62-93227 to obtain a racemic compound having a melting point of 143.4°C and a purity of 99.4%.

REFERENCE EXAMPLE 2

Preparation of R-(+)-(E)-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile (Compound (A)):

The racemic compound (100 g) obtained in Reference Example 1 was dissolved in 700 to 800 ml of acetone with heating to prepare a supersaturated solution. To this solution was added about 10 mg of a seed crystal of the optically active substance obtained by the process disclosed in JP-A-2-275877, followed by cooling to 25°C and leaving for 4 to 15 hours,

during which composition of the crystallized solution was analyzed by HPLC using an optical active column and the filtration point was determined. The precipitating crystals were collected by filtration and repeatedly subjected to the same procedure to obtain 25 g of R-enantiomer having an optical purity of 99.0%ee. In the above examples, the optical purity was calculated from area percentage in HPLC using an optical active HPLC column (Chiralcel ODR (trademark, Daicel Chemical Industry Ltd.)).

FORMULATION EXAMPLE 1

Compound (A) or (B)	10 parts
Magnesium stearate	10 parts
Lactose	80 parts

The above ingredients were uniformly mixed and the mixture was made into powders or fine particles to obtain a powder preparation.

FORMULATION EXAMPLE 2

Compound (A) or (B)	50 parts
Starch	10 parts
Lactose	15 parts
Ethylcellulose	20 parts
Polyvinyl alcohol	5 parts
Water	30 parts

The above ingredients were uniformly mixed and kneaded, and then the mixture was ground. The resulting particles were sifted to obtain a granular preparation.

FORMULATION EXAMPLE 3

Compound (A) or (B)	0.5 part
Nonionic surface active agent	2.5 parts
Physiological saline solution	97 parts

5 The above ingredients were heated and mixed, and then sterilized to obtain an injection.

FORMULATION EXAMPLE 4

Compound (A) or (B)	0.01 part
0.5% Carboxymethylcellulose	99.99 parts

10 The former was suspended in the latter to obtain a suspension.

FORMULATION EXAMPLE 5

Compound (A) or (B)	1 part
Polyethylene glycol 400	99 parts

15 The above ingredients were mixed to dissolve the compound (A) or (B) to obtain a liquid preparation for painting.

FORMULATION EXAMPLE 6

Compound (A) or (B)	2 parts
Polyethylene glycol 400	49 parts
Polyethylene glycol 4000	49 parts

20 The above ingredients were mixed by heating to dissolve Compound (A) or (B), and the obtained mixture was cooled to obtain an ointment.

FORMULATION EXAMPLE 7

Compound (A) or (B)	3 parts
1,2-Propanediol	5 parts
Glycerol stearate	5 parts
Spermaceti	5 parts
Isopropyl myristate	10 parts
Polysorbate	4 parts

A mixture of the above ingredients was heated and cooled, and 68 parts of water was added thereto with stirring to obtain a cream.

FORMULATION EXAMPLE 8

One part of Compound (A) or (B), 5 parts of benzyl alcohol, 30 parts of ethanol and 47 parts of propylene glycol were mixed to dissolve Compound (A) or (B). Then, an aqueous solution comprising 1 part of Hiviswako 104 (trademark, Wako Junyaku Co., Ltd.) and 15 parts of purified water to obtain a uniform solution was added to this solution. Next, 1 part of diisopropanolamine was added thereto with stirring to obtain a gel preparation.

FORMULATION EXAMPLE 9

One part of Compound (A) or (B) was dissolved in 5 parts of benzyl alcohol and 5 parts of diethyl sebacate, and thereto were added 5 parts of cetyl alcohol, 6 parts of stearyl alcohol, 1 part of sorbitan monostearate and 8 parts of polyoxyethylene monostearate, followed by heating to 70°C to dissolve them. To the resulting uniform solution kept at 70°C

was added a purified water heated to 70°C, followed by cooling with stirring to obtain a cream composition.

TEST EXAMPLE 1

In vitro Activity against *trichophyton* spp.:

5 Minimum inhibitory concentrations (MICs) were
determined by the twofold macro-broth dilution method with
Sabouraud's glucose broth which constituted with 1% bacto-
peptone and 4% glucose. To each tube containing 9.8 ml of the
broth, 0.1 ml of each testing compound dissolved in DMSO and
10 0.1 ml of a conidial suspension (1×10^6 conidia/ml) were added.
The fungal growth was observed after incubation for 7 days at
27°C. The MIC was determined as the lowest drug concentration
which prevented a visible fungal growth. The results are shown
in Table 1.

TABLE 1

MIC ($\mu\text{g/ml}$)					
Strain	Compound (A)	Compound (B)	Racemic Compound (A)	Racemic Compound (B)	TBF
A					
5	IFO 5466	0.02	0.02	0.04	0.02
	IFO 5809	0.005	0.005	0.01	0.01
	IFO 5810	0.005	0.005	0.01	0.005
	IFO 5811	0.02	0.01	0.04	0.01
	IFO 5929	0.01	0.01	0.02	0.01
10	TIMM 1189	0.01	0.01	0.04	0.01
	TIMM 1814	0.02	0.02	0.04	0.01
	TIMM 1815	0.02	0.02	0.04	0.02
	TIMM 1817	0.02	0.01	0.04	0.01
	TIMM 2789	0.005	0.0025	0.01	0.0025
B					
15	IFO 5467	0.0013	0.0025	0.005	0.005
	IFO 5807	0.0025	0.0025	0.01	0.005
	IFO 5808	0.0025	0.0025	0.01	0.005
	IFO 6203	0.0025	0.0013	0.005	0.0025
	IFO 6204	0.0025	0.0025	0.01	0.005
20	IFO 9185	0.0013	0.0013	0.0025	0.0025
	TIMM 1822	0.0013	0.00063	0.005	0.0025
	TIMM 1823	0.0025	0.0013	0.01	0.0025
	TIMM 1824	0.0013	0.0013	0.005	0.0013
	TIMM 1830	0.00063	0.00063	0.0013	0.00063

(Notes) A: *Trichophyton mentagrophytes*

B: *Trichophyton rubrum*

TBF: (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-
1-naphthalenemethanamine hydrochloride

5 (general name: terbinafine)

Racemic Compounds (A) and (B) are racemic mixtures of
Compounds (A) and (B), respectively.

TEST EXAMPLE 2

Therapeutic Efficacy on Experimental Tinea Pedis in Guinea Pigs
10 with Compound (A):

Male Hartley guinea pigs (Japan SLC Inc.) weighing 400
to 620 g were used for the infection study. One side of a
paper disc (1.5 mm thick x 8 mm diameter) was covered with a
piece of aluminum foil while the other side was free to carry
15 the inoculum suspension. The disc was immersed with 50 μ l of
the inoculum suspension (*trichophyton mentagrophytes* TIMM 2789,
 1×10^8 conidia/ml), and was then fixed on the planta pedis of
animal feet with an adhesive elastic tape. The disc was
removed on the seventh day postinfection. Each agent dissolved
20 in PEG 400 (0.1 ml/locus) was topically applied to the whole
soles of guinea pigs once a day for 3 consecutive days,
starting on the 10th day postinfection. Five days after the
last treatment, the skin tissue from each planta pedis and the
corresponding tarsus of all animals was cut into small blocks
25 (about 2 x 2 mm). Ten skin blocks obtained from each part of

the foot were implanted on a Sabouraud's glucose agar plate containing antibiotics, and were cultured at 27°C for 14 days. The skin blocks yielding fungal growth were regarded as culture-positive, and the foot (planta pedis plus tarsus) with more than one culture-positive skin block was considered fungus-positive. In addition, the intensity of infection was assessed by the scores based on the number of culture-positive skin blocks. Namely, +10, +9, +8, +7, +6, +5, +4, +3, +2, +1 or 0 was given as the score according to the corresponding number of culture-positive skin blocks out of ten skin blocks studied. Statistical analyses for the rate of fungus-positive feet and the average intensity of infection were assessed by Fisher's exact probably test and Mann-Whitney's U-test, respectively. The results are shown in Table 2.

TABLE 2

Test group	Fungus-positive rate The number of positive feet/The total number of feet (%)	Average intensity of infection	
		Planta pedis	Tarsus
0.5% Compound (A)	2/10 (20) ^{A,B)}	+0.3 ^{A,B)}	0 ^{A,B)}
1% Compound (A)	0/10 (0) ^{A,B,C)}	0 ^{A,B)}	0 ^{A,B)}
5 1% Racemic compound (A)	4/10 (40) ^{A,B)}	+0.6 ^{A,B)}	+0.2 ^{A,B)}
Untreated	10/10 (100)	+7.7	+5.4
PEG 400	10/10 (100)	+7.9	+4.8

(Notes) A: $p < 0.01$ vs untreated control group

10 B: $p < 0.01$ vs PEG 400 treated control group

C: $p < 0.05$ vs 1% Racemic Compound (A) treated group

15 The fungus-positive rate of the untreated group was 100% and fungi were detected from all of the infected feet. In terms of the average intensity of infection, a high value of +7.7 was obtained in the planta pedis, but it was +5.4 in the tarsus. Thus, this shows a tendency that the degree of infection in the tarsus was lower than in the planta pedis. Nearly the same results were obtained in the PEG 400 treated group and the curative effect by the solvent was not

20 recognized. The 1% Racemic Compound (A) treated group showed a significant curative effect as compared with the untreated group and the PEG 400 treated group, but the fungus-positive

rate was 40% and the average intensity of infection of the planta pedis and the tarsus was +0.6 and +0.2, respectively, and fungi were detected from four feet among the inoculated ten feet. In the 0.5% Compound (A) treated group, the fungus-positive rate was 20%, which shows that the effect of Compound (A) was twice that of 1% Racemic Compound (A), and in the 1% Compound (A) treated group, the remarkable effect that all of the infected feet were cure fungus-negative was obtained, namely, mycologically complete healing was attained.

As a result of the comparison between Compound (A) and Racemic Compound (A), it became clear that Compound (A) showed a curative effect markedly higher than Racemic Compound (A) at the same concentration and that when 0.5% Compound (A) and 1% Racemic Compound (A) which were the same in concentration in terms of active ingredient (A.I.) which was Compound (A) were compared, Compound (A) showed the higher effect more than twice that of 1% Racemic Compound (A). Considering MIC for *T. mentagrophytes* TIMM 2789 used for the test, it is clear that Compound (A) had *in vitro* antifungal activity of 4 times that of Racemic Compound (A), and this difference in antifungal action was reflected also in the curative test for the infection model *in vivo*.

TEST EXAMPLE 3

In vitro antifungal activity against *Candida albicans*:

MICs were determined by the twofold micro-broth dilution method with RPMI 1640 buffered with morphorino-
propanesulfonic acid to a final molarity of 0.165 M (pH 7.0).
One hundred μ l of a yeast cell suspension (1 to 5×10^3 cells/ml)
and 100 μ l of the compound-containing medium were pipetted into
each well flat-bottomed microtiter plates. After incubation
for 48 hours at 35°C, the turbidity of each well was measured
at 630 nm. The MIC was determined as the lowest drug
concentration which showed 80% inhibition of a control fungal
growth (as measured in turbidity-increase). The results are
shown in Table 3.

TABLE 3

		MIC ($\mu\text{g/ml}$)				
		Compound	Compound	Racemic	Racemic	
		(A)	(B)	Compound	Compound	
		(A)	(B)	(A)	(B)	TBF FCZ
5	IFO 0197	0.0625	0.0625	0.25	0.125	>32.0 0.25
	IFO 0579	0.0313	0.0313	0.0625	0.0625	>32.0 0.125
	IFO 1269	0.0625	0.0625	0.125	0.0625	4.0 0.25
	IFO 1270	0.25	0.25	1.0	0.25	>32.0 0.25
	IFO 1385	0.0625	0.0625	0.25	0.125	>32.0 0.25
10	IFO 1386	0.125	0.125	0.25	0.25	>32.0 0.5
	TIMM 3163	4.0	16.0	16.0	>32.0	>32.0 16.0
	TIMM 3164	0.25	0.5	0.5	0.5	>32.0 2.0
	TIMM 3165	2.0	2.0	4.0	4.0	>32.0 >32.0
	TIMM 3166	1.0	1.0	2.0	4.0	>32.0 8.0

(Note) FCZ: 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol (general name: fluconazole)

15

TEST EXAMPLE 4

In vitro antifungal activity of Compound (B) against *Aspergillus fumigatus*:

MICs were determined by the twofold agar dilution method with casitone agar which constituted with 0.9% bacto-casitone, 1% bacto-yeast extract, 2% glucose, 0.1% KH_2PO_4 , 0.1% Na_2HPO_4 , 1% $\text{Na}_3\text{C}_6\text{H}_5\text{O}_7$, and 1.6% agar. A loopful of each inoculum (1×10^6 conidia/ml) was streaked onto the agar plate containing a compound, and a fungal growth was observed after incubation for 48 hours at 35°C. The MIC was determined as the lowest

drug concentration which prevented a visible fungal growth.
The results are shown in Table 4.

TABLE 4


		MIC (µg/ml)					
		Compound	Compound	Racemic	Racemic		
		A	B	Compound	Compound		
		A	B	A	B	TBZ	ITZ
5	TIMM 0063	0.00063	0.00063	0.0013	0.0013	1.28	0.04
	TIMM 0078	0.00063	0.00063	0.0013	0.0013	1.28	0.04
	TIMM 1728	0.0013	≤0.00031	0.0013	0.00063	1.28	0.08
	TIMM 1767	0.0013	0.00063	0.0025	0.0013	1.28	0.08

(Note) ITZ: (±)-1-sec-Butyl-4-[p-[4-[p-[[2R*,4S*]-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl-Δ²-1,2,4-triazolin-5-one
(general name: itraconazol)

10

CLAIMS

1. A pharmaceutical composition comprising as an active ingredient R-(+)-(E)-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile represented by the following formula (I):




wherein R represents a hydrogen atom or a chlorine atom, or a pharmaceutically acceptable salt thereof; together with a pharmaceutically acceptable carrier or diluent.

2. The pharmaceutical composition as claimed in claim 1, wherein the active ingredient is R-(+)-(E)-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition as claimed in claim 1, wherein the active ingredient is R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or a pharmaceutically acceptable salt thereof.

4. R-(-)-(E)-[4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or a salt thereof.

5. A process for producing R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile represented by the following (B):



which comprises reacting an optically active glycol derivative represented by the following formula (II) or an equivalent thereof with a dithiolate salt represented by the following formula (III):




wherein X_1 and X_2 are the same or different and each represents a methanesulfonyloxy group, a benzenesulfonyloxy group, a p-toluenesulfonyloxy group, or a halogen atom:



(III)

wherein M represents an alkali metal atom.

6. A method for preventing or treating mycosis which comprises administering to human or animals in need of such prevention or treatment a pharmaceutically effective amount of R-(+)-(E)-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile represented by the following formula (I):




(I)

wherein R represents a hydrogen atom or a chlorine atom, or a pharmaceutical acceptable salt thereof; optionally together with a pharmaceutical acceptable carrier or diluent.

7. The method as claimed in claim 6, wherein R-(+)-(E)-[4-(2-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or a pharmaceutically acceptable salt thereof is administered.

8. The method as claimed in claim 6, wherein R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or a pharmaceutically acceptable salt thereof is administered.

5 9. Use of R-(+)-(E)-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile represented by the following formula (I):



(I)

wherein R represents a hydrogen atom or a chlorine atom, or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition.

10. Use of R-(+)-(E)-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition.

11. Use of R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition.